Pegvisomant - Pfizer

Drug Profile

Pegvisomant - Pfizer

Alternative Names: B2036-PEG; Somavert; Trovert

Latest Information Update: 17 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genentech; Omeris
  • Developer Pfizer
  • Class Anterior pituitary hormones; Recombinant proteins
  • Mechanism of Action Somatotropin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acromegaly
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acromegaly
  • Discontinued Cancer; Diabetic retinopathy

Most Recent Events

  • 13 Nov 2017 The Scottish Medicines Consortium accepts pegvisomant for routine use by NHS Scotland for the treatment of Acromegaly
  • 14 Jul 2017 EMA approves pegvisomant 25mg and 30mg for Acromegaly in European Union (SC) before July 2017
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top